Perseus Proteomics Inc. (TYO:4882)

Market Cap	6.03B
Revenue (ttm)	120.00M
Net Income (ttm)	-904.00M
Shares Out	14.75M
EPS (ttm)	-63.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,800
Average Volume	259,440
Open	409.00
Previous Close	409.00
Day's Range	407.00 - 412.00
52-Week Range	355.00 - 1,113.00
Beta	0.53
RSI	47.48
Earnings Date	Aug 14, 2025

About MorphoSys AG

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell;...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2001
• Employees: 32
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4882

Financial Performance

In 2024, Perseus Proteomics's revenue was 120.00 million, an increase of 20.00% compared to the previous year's 100.00 million. Losses were -904.00 million, -18.12% less than in 2023.